Telomerase mediated telomere altering compounds

Patent metadata

Field	Value
Publication number	US-10463685-B2
Application number	US-201414247967-A
Country	US
Kind code	B2
Filing date	Apr 8, 2014
Priority date	Apr 8, 2013
Publication date	Nov 5, 2019
Grant date	Nov 5, 2019

Abstract

Methods for treating a telomerase-expressing cell characterized by an over-activation of telomerase in a subject in need thereof comprising administering a pharmaceutical composition comprising a first amount of a 6-mercaptopurine analog, and a second amount of a telomerase inhibitor, wherein the first amount and the second amount together comprises an amount effective to reduce stability of telomere length and to induce cell death in the telomerase-expressing cell are provided. The methods can be used to treat patients with lung cancer, colon cancer, or cervical cancer.

First claim

What is claimed is:

1. A method of treating a telomerase-expressing lung cancer cell or colon cancer cell characterized by an over-activation of telomerase in a subject in need thereof with lung cancer or colon cancer, comprising administering
a pharmaceutical composition comprising a compound analogue according to Formula III:

wherein R 1 is H a pharmaceutically acceptable salts or a polymorph thereof;

wherein the pharmaceutical composition is administered in an amount effective to reduce stability of telomere length and to induce cell death in the telomerase-expressing lung cancer cell or colon cancer cell.

2. The method of claim 1 , wherein the pharmaceutical composition is administered in an amount between 0.5-3 mg per 1 kg of the subject per day.

3. The method of claim 1 , wherein the administering of the pharmaceutical composition is at least twice per week for at least 2 weeks, at least 4 weeks, at least 6 weeks, at least 8 weeks, or at least 12 weeks.

4. The method of claim 1 , wherein the administering of the pharmaceutical composition is orally or by injection.

5. The method of claim 1 , wherein the administering of the pharmaceutical composition is by intratumoral injection.

6. The method of claim 1 , wherein the subject is a human being.

7. The method of claim 1 , wherein the telomerase-expressing lung cancer cell or colon cancer cell characterized by overactivation of telomerase is a telomerase-expressing tumor cell.

8. The method of claim 7 , wherein the amount effective to reduce stability of telomere length and induce cell death in the telomerase-expressing lung cancer cell or colon cancer cell effects a reduction in tumor size of a lung tumor or colon tumor comprising the telomerase-expression lung cancer cell or colon cancer cell or a reduction in tumor growth rate of a lung tumor or colon tumor comprising the telomerase-expressing lung cancer cell or colon cancer cell.

Assignees

• Univ Texas

Inventors

• Shay Jerry W
• Gryaznov Sergei M

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/708

  having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid · CPC title

• A61K31/7088

  Compounds having three or more nucleosides or nucleotides · CPC title

• A61K31/7076 Primary

  containing purines, e.g. adenosine, adenylic acid · CPC title